期刊文献+

肾性高血压临床特点及治疗对策 被引量:22

Clinical characteristics and treatment strategy of renal hypertension
下载PDF
导出
摘要 目的观察肾性高血压的临床特点,分析肾性高血压与原发性高血压降压治疗异同。方法回顾性分析我院自2007年1月至2009年12月收诊的高血压患者,观察组均为确诊肾性高血压患者326例;对照组均为原发性高血压患者673例,对两组进行年龄、血压情况对比,并进行降压治疗。结果观察组平均年龄低于对照组,差异有显著性(P<0.05),且<20岁和<30岁患者比率明显高于对照组,差异有非常显著性(P<0.01);观察组平均血压和高峰血压均明显高于对照组,差异有显著性(P<0.05)。观察组需使用静脉降压药物抢救治疗的65例(19.9%);对照组45例(6.7%)。观察组需4种降压药物联合治疗的病人数186例(57.1%);对照组90例(13.4%)。两组需要使用静脉降压药物抢救治疗和需要4种降压药物联合治疗方面有显著差异(P<0.01)。结论肾性高血压的危害大,应注重对患者血压的控制,应针对病情的不同选取不同的降压药物,并采用联合治疗的方法。 Objective To study the clinical characteristics of renal hypertension, and to analyze the difference in antihypertensive treatment between renal hypertension and essential hypertension.Methods The clinical data of patients with hypertension in this hospital during January 2007 to December 2009 were retrospectively reviewed and analyzed. Altogether 326 cases of renal hypertension were allocated into observation group and 673 cases of essential hypertension were in control group. The age and status of blood pressure were compared in patients between these two groups after antihypertensive treatment.Results The age range of patients in observation group was as follows: 34 cases 30, 11 cases 20 and others 30 years old. There were only 2 cases with age range 30 years old in patients of control group. There was no one less than 20 years old in both groups. Sixty five cases(19.9%) in observation group and 45 cases(6.7%) in control group needed intravenous administration of antihypertensive drugs. There was significant difference in age, systolic and diastolic blood pressure (P0.05) between these two groups . One hundred and eighty six (57.1%) cases in observation group and 90 (13.4%) cases in control group needed 4 kinds of antihypertensive drugs for treatment. There was significant difference in number of patients needed intravenous antihypertensive drugs for treatment (P0.01).ConclusionRenal hypertension is much harmful than essential hypertension. Physicians should pay more attention on control of blood pressure in these patients and select different antihypertensive drugs according to different conditions, and it is important to apply combination of therapeutic methods for treatment.
作者 薛志强
出处 《临床和实验医学杂志》 2010年第24期1845-1846,共2页 Journal of Clinical and Experimental Medicine
关键词 肾性高血压 原发性高血压 临床治疗 Renal hypertension Essential hypertension Clinical treatment
  • 相关文献

参考文献7

  • 1马骥,陈靖,林善锬,陈楠,袁伟杰,王笑云,刘必成,陈健,徐玉兰,张欣州,邓安国,舒贵阳,张金黎,刘惠.氯沙坦降低中国慢性肾脏病患者尿蛋白的临床研究[J].中华内科杂志,2004,43(12):932-933. 被引量:5
  • 2Soulez G,Oliva VL,Turpin S,,et al.Imaging of renovascular hypertension:respective values of renal scintigraphy,renal Doppler US,and MR angiography[J].Radiographics,2000,20(5):1355-1368.
  • 3Andersen S,Tarnow L,Rossing P,et al.Renoprotective effects of a slotensin II receptor blockade in type I diabetic patients with diabetic nephropathy[J].Kidney Int,2000,57(2):601-606.
  • 4Kalra PA.Renal specific secondary hypertension[J].J Ren Care,2007,33(1):4-10.
  • 5刘章锁.肾性高血压治疗进展[J].实用医院临床杂志,2008,5(4):22-24. 被引量:17
  • 6Fain SB,King BF,Breen JF,et al.High-spatialresolution contrast-enhanced MR angiography of the renal arteries:a prospective comparison with digital subtraction angiography[J].Radiology,2001,218(2):481-490.
  • 7Hou FF,Xie D,Zhang X,et al.Renoprotection of Optimal Antiproteinuric Doses(ROAD)Study:a randomized eontrolled study of benazepril and losanan in chronic renal insufficiency[J].J Am Soc Nephrol,2007,18(5):1889-1898.

二级参考文献15

  • 1[1]Ruilope LM,Salvetti A,Jamerson K,et aL Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study[J].J Am Soc Nephrol,2001,12(2):218-225.
  • 2[2]Maschio G,Alberti D,LocateUi F,et aL Angiotensin-converting enzyme inhibitors and kidney protection:the AIPRI triaL The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group[J].J Cardiovasc Pharmacol,1999,33(suppl 1):S16-20.
  • 3[3]Hou FF,Zhang X,Zhang GH,et al.Efficacy and safety of benazepril for advanced chronic renal insufficiency[J].N Engl J Med,2006,354 (2):131-140.
  • 4[4]Ruggenenti P,Pema A,Gherardi G,et aL Renal function and require-ment for dialysis in chronic nephropathy patients on long-term ramipril:REIN follow-up trial.Gruppo Italiano di Studi Epidemiologici in Nefrolo-gia (GISEN)[J].Lancet,1998,352(9136):1252-1256.
  • 5[5]Parring HH,Lehnert H,Brochner MJ,et aL The effect of irbesartan on the development of diabetic ncphropathy in patients with type 2 diabetes[J].N Engl J Med,2001,345(12):870-878.
  • 6[6]Giancarlo V,Nigel MW.Microalbuminuria reduction with valsartan in patients with type-2 diabetes mellitus:a blood pressure-independent effect[J].Circulation,2002,106(3):672-678.
  • 7[7]Lewis EJ,Nunsicker LG,Clarke WR,et aL Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephrcpathy due to type 2 diabetes[J].N Engl J Med,2001,345(12):851-860.
  • 8[8]Brenner BM,Cooper ME,Zecuw D,et al.Effects of losartan on renal and cardiovascular outcomes in patients with type 2diabetes and nephrop-athy[J].New Engl J Meal,2001,345(12):861-869.
  • 9[9]Julius S,Kjeldsen SE,Weber M,et aL Outcomes in hypertensive pa-tients at high cardiovascular risk treated with regimens based on valsrtan or andodipine:the VALUE randomized trial[J].Lancet,2004,363(9426):2022-2031.
  • 10[10]Wachtell K,Dahlof B,Rokkedal J,et aL Change of left ventrieular geo-metric pattern after 1 year of antihypertensive treatment:the Losartan In-tervention For Endpoint reduction in hypertension(LIFE) study[J].J Am Heart,2002,144(6):1057-1064.

共引文献20

同被引文献121

引证文献22

二级引证文献167

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部